Mandate

Vinge advises Gotlandsbolaget on its investment in shipping of the future

February 14, 2025 Maritime and Transport Law

Gotlandsbolaget has taken an important step towards a more sustainable future by ordering the high-speed catamaran Gotland Horizon X, which will be powered by fossil-free fuels. For Vinge, it has been a privilege to provide advice to Gotlandsbolaget during the process.

The vessel, built by the Australian shipyard Austal, will be a pioneering example of the sustainable ferry service of the future. The advice has covered the drafting and negotiation of shipbuilding contracts as well as intellectual property issues. With our support, Gotlandsbolaget, Sweden’s oldest passenger shipping company, has been able to focus on developing a solution that not only benefits the ferry-service to Gotland, but also contributes to the transition of shipping towards a climate-neutral future.

A sustainable solution for Gotland transport

The Gotland Horizon X will be a fast catamaran with room for 1,500 passengers and 400 cars, which can run on several types of fossil-free fuels. The vessel will be able to travel at 29 knots, giving a crossing time between Gotland and the mainland of just over 3 hours.

Vinge looks forward to following the development and is proud to have been part of Gotlandsbolaget's important investment in sustainability and innovation.

Vinge’s team consisted of Paula Bäckdén, Alexander Lindeberg and Imola Szanto Francsics.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026